SCHEMBL13685729

SCHEMBL13685729

C=CCNC(=O)C(=O)[C@@H]1CCCCCCCC[C@@H](C)[C@H](NC(=O)NC2(CS(=O)(=O)C(C)(C)C)CCCCC2)C(=O)N2C[C@H]3[C@@H]([C@H]2C(=O)N1)C3(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8291770 0.92 — —
SCHEMBL7857262 0.92 — —
SCHEMBL12608040 0.92 — —
SCHEMBL16297967 0.92 — —
SCHEMBL14597293 0.92 — —
SCHEMBL12606655 0.88 — —
SCHEMBL7860508 0.86 — —
SCHEMBL12607439 0.85 ADAM17 (0.31) —
SCHEMBL12856023 0.83 — —
SCHEMBL12608392 0.83 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7592419-B2 Macrocyclic inhibitors of hepatitis C virus NS3-serine protease SCHERING CORPORATION (US) 2009-09-22 — — US disclosed
US-7592419-B2 Macrocyclic inhibitors of hepatitis C virus NS3-serine protease SCHERING CORPORATION (US) 2009-09-22 — — US disclosed
Send feedback